<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03515044</url>
  </required_header>
  <id_info>
    <org_study_id>RNHE2041</org_study_id>
    <nct_id>NCT03515044</nct_id>
  </id_info>
  <brief_title>Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)</brief_title>
  <acronym>OHE</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets
      Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to assess the efficacy of rifaximin SSD plus lactulose
      versus placebo plus lactulose for the treatment of overt hepatic encephalopathy (OHE). The
      secondary objectives of this study are to assess the safety of rifaximin SSD in subjects with
      OHE and to assess the effects of treatment with rifaximin SSD on key secondary endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2018</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Blinding will be maintained in the QD SSD cohorts by administering placebo as the second daily dose.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to OHE resolution determined using the Hepatic Encephalopathy Grading Instrument (HEGI).</measure>
    <time_frame>3 to 12 hours after administration</time_frame>
    <description>Major diagnostic criteria include: (1) disorientation (time, place, and/or person), or (2) presence of both lethargy and asterixis, or (3) coma. Inter- and intra-rater HEGI reproducibility</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">325</enrollment>
  <condition>Overt Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Cohort 1 40 mg Rifaximin SSD once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg Rifaximin immediate release (IR) rifaximin SSD once daily (QD) and lactulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 40 mg Rifaximin SSD twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg Rifaximin immediate release (IR) rifaximin SSD twice daily (BID) and lactulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 80 mg Rifaximin SSD once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg Rifaximin sustained extended release (SER) rifaximin SSD once daily (QD) and lactulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 80 mg Rifaximin SSD twice daiy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4 80 mg Rifaximin SSD twice daily (BID) and lactulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 Placebo twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SSD placebo twice daily (BID) and lactulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40 mg Rifaximin SSD once daily</intervention_name>
    <description>SSD once daily (QD) and lactulose</description>
    <arm_group_label>Cohort 1 40 mg Rifaximin SSD once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40 mg Rifaximin SSD twice daily</intervention_name>
    <description>SSD twice daily (BID) and lactulose</description>
    <arm_group_label>Cohort 2 40 mg Rifaximin SSD twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>80 mg Rifaximin SSD once daily</intervention_name>
    <description>SSD once daily (QD) and lactulose</description>
    <arm_group_label>Cohort 3 80 mg Rifaximin SSD once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>80 mg Rifaximin SSD twice daily</intervention_name>
    <description>SSD twice daily (BID) and lactulose</description>
    <arm_group_label>Cohort 4 80 mg Rifaximin SSD twice daiy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered twice daily (BID) and lactulose</description>
    <arm_group_label>Cohort 5 Placebo twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lactulose</intervention_name>
    <description>to be taken in the recommended adult size dosage.</description>
    <arm_group_label>Cohort 1 40 mg Rifaximin SSD once daily</arm_group_label>
    <arm_group_label>Cohort 2 40 mg Rifaximin SSD twice daily</arm_group_label>
    <arm_group_label>Cohort 3 80 mg Rifaximin SSD once daily</arm_group_label>
    <arm_group_label>Cohort 4 80 mg Rifaximin SSD twice daiy</arm_group_label>
    <arm_group_label>Cohort 5 Placebo twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female age 18 to 75 years of age (inclusive) at the time of screening.

          -  Females of childbearing potential, defined as a female who is fertile following
             menarche, must have a negative serum pregnancy test at screening and agree to use an
             acceptable method of contraception throughout their participation in the study.

        Note: Female subjects who have been surgically sterilized (e.g., hysterectomy or bilateral
        tubal ligation) or who are postmenopausal (defined as total cessation of menses for &gt; 1
        year) will not be considered &quot;female subjects of childbearing potential&quot;.

          -  Subject is hospitalized with liver cirrhosis and/or OHE and has a confirmed diagnosis
             of OHE at Baseline.

          -  Subject has a Grade 2 or Grade 3 HE episode according to the HE Grading Instrument
             (HEGI) following 8 to 12 hours of intravenous (IV) hydration and lactulose treatment.

        Exclusion Criteria:

          -  Subject has an uncontrolled major psychiatric disorder including major depression or
             psychoses as determined by the investigator.

          -  Subject has been diagnosed with an infection for which they are currently taking oral
             or parenteral antibiotics, which cannot be discontinued at time of enrollment. Note:
             Subjects currently taking Rifaximin are not excluded

          -  Subject shows presence of intestinal obstruction or has inflammatory bowel disease.

          -  Subject has uncontrolled Type 1 or Type 2 diabetes. Note: Subjects with controlled
             diabetes may be enrolled if they are on stable doses of oral hypoglycemic drugs for at
             least 3 months prior to screening, and demonstrate clinically acceptable blood glucose
             control at Baseline, as determined by the investigator.

          -  Subject has an active malignancy (exceptions: non-melanoma skin cancers).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsey Mathew</last_name>
    <role>Study Director</role>
    <affiliation>Valeant Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lindsey Mathew</last_name>
    <phone>9089270873</phone>
    <email>lindsey.mathew@bauschhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Valeant Site 18</name>
      <address>
        <city>Corona Del Mar</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 15</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 19</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 04</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 13</name>
      <address>
        <city>Bristol</city>
        <state>Connecticut</state>
        <zip>06010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 08</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 05</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 33</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 03</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 07</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 01</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 25</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 24</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 27</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 36</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 09</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 28</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 17</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 23</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 11</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 26</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 10</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 12</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 16</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 22</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 35</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 31</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 02</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 37</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 30</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 06</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 21</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 14</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valeant Site 20</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 12, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2018</study_first_posted>
  <last_update_submitted>March 8, 2019</last_update_submitted>
  <last_update_submitted_qc>March 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

